Novartis AG (NVSEF)
OTC: NVSEF
· Real-Time Price · USD
132.49
2.49 (1.92%)
At close: Oct 15, 2025, 9:30 AM
132.49
0.00%
Pre-market: Oct 15, 2025, 09:30 AM EDT
Novartis Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
Revenue | 51.72B | 46.66B | 51.83B | 52.88B |
Cost of Revenue | 12.83B | 12.02B | 15.49B | 15.87B |
Gross Profit | 38.9B | 34.64B | 36.34B | 37.01B |
Operating Income | 14.54B | 9.77B | 9.2B | 11.69B |
Interest Income | 550.78M | 436M | 389.37M | 71.15M |
Pretax Income | 13.64B | 9.12B | 8.37B | 26.14B |
Net Income | 11.94B | 14.85B | 6.96B | 24.02B |
Selling & General & Admin | 12.57B | 12.49B | 14.25B | 14.89B |
Research & Development | 10.02B | 11.37B | 10B | 9.54B |
Other Expenses | 1.76B | 1.01B | -101.22M | 269.57M |
Operating Expenses | 24.35B | 24.87B | 27.14B | 25.32B |
Interest Expense | 1.01B | 855M | 860.33M | 906.93M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 37.18B | 36.89B | 42.63B | 41.19B |
Income Tax Expense | 1.7B | 551M | 1.42B | 2.12B |
Shares Outstanding (Basic) | 2.02B | 2.08B | 2.18B | 2.24B |
Shares Outstanding (Diluted) | 2.04B | 2.09B | 2.2B | 2.26B |
EPS (Basic) | 5.92 | 7.63 | 3.29 | 10.73 |
EPS (Diluted) | 5.87 | 7.58 | 3.27 | 10.65 |
EBITDA | 20.71B | 19.52B | 15.21B | 17.17B |
EBIT | 14.65B | 10.68B | 8.28B | 11.73B |
Depreciation & Amortization | 6.07B | 8.83B | 6.92B | 5.44B |
Source: Financial Modeling Prep. Financial Sources.